| Today’s Big NewsJan 2, 2025 |
| By Nick Paul Taylor Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. |
|
|
|
By Ben Adams Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate asset to its pipeline. |
By Nick Paul Taylor Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates and other assets in the final few days of 2024. |
By James Waldron The festive season may be a chance to rest up and recharge—but tell that to biotech dealmakers, who have been as busy as ever. |
By Nick Paul Taylor Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage readouts on Neumora’s lead drug candidate has ended in failure, wiping more than 80% off the value of the biotech. |
By James Waldron Valo Health’s Rho kinase (ROCK) 1 and 2 inhibitor has failed to reduce the severity of diabetic retinopathy in a phase 2 trial, leading the Flagship-founded biotech to drop the candidate. |
By Gabrielle Masson CARsgen Therapeutics’ CAR-T improved progression-free survival (PFS) compared to approved therapies for patients with advanced stomach cancer in a phase 2 trial. |
By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2024, the FDA gave a thumbs-up to more than xx new treatments, which was down from 60-plus new drugs in 2023. |
By Angus Liu Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the cancer immunotherapy. |
By Darren Incorvaia Rising costs and a boom in obesity trials and AI are some of the predicted trends for the clinical trial industry in 2025. |
By Fraiser Kansteiner While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts of the new class of cardiometabolic medicines have been consistently hamstrung by manufacturing and supply constraints. That said, "positive signals" are emerging around the future of GLP-1 supply, analysts at ZS opined. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," we explore how teaching kids social-emotional skills early can transform their lifelong wellbeing. |
|
|---|
|
|
| |
|
